CSIMarket
 


Kiromic Biopharma Inc   (KRBP)
Other Ticker:  
 
 

KRBP's Net Cash Flow Growth by Quarter and Year

Kiromic Biopharma Inc 's Net Cash Flow results by quarter and year




KRBP Net Cash Flow (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December -1.18 0.21 -9.81 9.68
III Quarter September 1.68 -6.08 32.09 -1.46
II Quarter June 0.65 -8.61 -4.26 0.00
I Quarter March 1.41 -10.23 -2.82 0.00
FY   2.56 -24.71 15.20 8.22



KRBP Net Cash Flow fourth quarter 2023 Y/Y Growth Comment
Kiromic Biopharma Inc in the fourth quarter 2023 recorded net cash outflow of $ -1.18 millions.

Looking into fourth quarter 2023 results within Biotechnology & Pharmaceuticals industry 2 other companies have achieved higher Net Cash Flow growth. While Kiromic Biopharma Inc ' s Net Cash Flow no change of % ranks overall at the positon no. 291 in the fourth quarter 2023.




KRBP Net Cash Flow ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - 84.91 % -

Financial Statements
Kiromic Biopharma Inc 's fourth quarter 2023 Net Cash Flow $ -1.18 millions KRBP's Income Statement
Kiromic Biopharma Inc 's fourth quarter 2022 Net Cash Flow $ 0.21 millions Quarterly KRBP's Income Statement
New: More KRBP's historic Net Cash Flow Growth >>


KRBP Net Cash Flow (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September 158.46 % - - -
II Quarter June -53.9 % - - -
I Quarter March 571.43 % - - -
FY (Year on Year)   - - 84.91 % -




Net Cash Flow fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #3
Healthcare Sector #26
Overall #291

Net Cash Flow Y/Y Growth Statistics
High Average Low
201.43 % -109.12 % -267.81 %
(Jun 30 2022)   (Mar 31 2023)
Net Cash Flow fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #3
Healthcare Sector #26
Overall #291
Net Cash Flow Y/Y Growth Statistics
High Average Low
201.43 % -109.12 % -267.81 %
(Jun 30 2022)   (Mar 31 2023)

Net Cash Flow by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Kiromic Biopharma Inc 's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


KRBP's IV. Quarter Q/Q Net Cash Flow Comment
Recent results of -1.18 millions by Kiromic Biopharma Inc appear even worse if you take a look at 1.68 millions in the previous quarter.

Within Biotechnology & Pharmaceuticals industry Kiromic Biopharma Inc achieved highest sequential Net Cash Flow growth. While Kiromic Biopharma Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


KRBP's IV. Quarter Q/Q Net Cash Flow Comment
Recent accomplishment of -1.18 millions by Kiromic Biopharma Inc look even more unfavourable if you take a look at 1.68 millions in the third quarter.

Within Biotechnology & Pharmaceuticals industry Kiromic Biopharma Inc achieved highest sequential Net Cash Flow growth. While Kiromic Biopharma Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Kiromic Biopharma Inc 's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Net Cash Flow 12 Months Ending $ 2.56 $ 3.95 $ -3.81 $ -13.07 $ -24.71
Y / Y Net Cash Flow Growth (TTM) - - - - -
Year on Year Net Cash Flow Growth Overall Ranking # # # # #
Seqeuential Net Cash Flow Change (TTM) -35.17 % - - - -
Seq. Net Cash Flow Growth (TTM) Overall Ranking # 291 # 0 # 405 # 393 # 465




Cumulative Net Cash Flow growth Comment
In the Dec 31 2023 period, Kiromic Biopharma Inc had cumulative twelve months Net Cash Flow of $ 3 millions compare to net cash outflow of $ -25 millions a year ago.

Kiromic Biopharma Inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
201.43 %
-109.12 %
-267.81 %
 

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 26
S&P 500 # 291
Cumulative Net Cash Flow growth Comment
In the Dec 31 2023 period, Kiromic Biopharma Inc had cumulative twelve months Net Cash Flow of $ 3 millions compare to net cash outflow of $ -25 millions a year ago.

Kiromic Biopharma Inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
201.43 %
-109.12 %
-267.81 %
 


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 26
S&P 500 # 291




Other Net Cash Flow Growth
Biotechnology & Pharmaceuticals Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
KRBP's Net Cash Flow Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for KRBP's Competitors
Net Cash Flow Growth for Kiromic Biopharma Inc 's Suppliers
Net Cash Flow Growth for KRBP's Customers

You may also want to know
KRBP's Annual Growth Rates KRBP's Profitability Ratios KRBP's Asset Turnover Ratio KRBP's Dividend Growth
KRBP's Roe KRBP's Valuation Ratios KRBP's Financial Strength Ratios KRBP's Dividend Payout Ratio
KRBP's Roa KRBP's Inventory Turnover Ratio KRBP's Growth Rates KRBP's Dividend Comparisons



Companies with similar Net Cash Flow no change for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Dec 31 2023
Astrazeneca Plc-5.29%$ -5.287 millions
Lipocine Inc -6.98%$ -6.984 millions
Caredx Inc -14.62%$ -14.617 millions
Sophia Genetics Sa-16.41%$ -16.406 millions
Xencor Inc-17.78%$ -17.780 millions
Kronos Bio Inc -20.78%$ -20.784 millions
Earth Science Tech Inc -21.38%$ -21.381 millions
Hookipa Pharma inc -22.19%$ -22.193 millions
Anaptysbio Inc -24.22%$ -24.222 millions
Koru Medical Systems Inc-26.57%$ -26.570 millions
Abbott Laboratories-35.07%$ -35.069 millions
Lantheus Holdings Inc -37.16%$ -37.161 millions
Alcon inc -37.78%$ -37.778 millions
Inflarx N v -38.04%$ -38.037 millions
Novartis Ag-39.41%$ -39.413 millions
Argenx se-40.00%$ -40.005 millions
Gh Research Plc-40.04%$ -40.040 millions
Bright Minds Biosciences Inc -41.15%$ -41.154 millions
Enzon Pharmaceuticals inc -42.33%$ -42.332 millions
Myriad Genetics Inc -44.65%$ -44.653 millions
Elutia inc -46.46%$ -46.456 millions
Gilead Sciences Inc -46.70%$ -46.704 millions
Koninklijke Philips Nv-49.11%$ -49.110 millions
Avidity Biosciences Inc -49.45%$ -49.449 millions
Proqr Therapeutics N v -49.46%$ -49.460 millions
Protalix Biotherapeutics inc -49.52%$ -49.523 millions
Xeris Biopharma Holdings Inc -49.99%$ -49.994 millions
Altair International Corp -52.34%$ -52.344 millions
Macrogenics Inc -55.57%$ -55.574 millions
Atricure Inc -59.98%$ -59.983 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com